Current Issue : March/April 2012
Web Exclusives
Richard H. Stanford, PharmD, MS; Mahesh Kulakodlu, MS; James P. Burke, PhD; and Aylin A. Riedel, PhD
Physicians are prescribing 2 guideline-recommended asthma treatments for patients with similar baseline symptoms and past treatment patterns.
Kamyar Nasseh, PhD; Sharon Glave Frazee, PhD, MPH; Jay Visaria, PhD, MPH; Anna Vlahiotis, MA; and Yuhong Tian, PhD
The national cost of medication nonadherence associated with diabetes, dyslipidemia, and hypertension is significant in the United States.
Feng Zeng, PhD; Russell L. Knoth, PhD; Bimal V. Patel, PharmD, MS; John A. Bates, PhD; Suja Mathew, BS; and Yonghua Jing, PhD
Utilization management may reduce the ability of patients to maintain optimal drug therapy and could therefore lead to worse health outcomes.
Feng Zeng, PhD; Russell L. Knoth, PhD; Bimal V. Patel, PharmD, MS; Edward Kim, MD, MBA; Quynh-Van Tran, PharmD, BCPP; and Yonghua Jing, PhD
Among the commercially insured, benefit restrictions can impact atypical antipsychotic medication persistence and adherence in patients who have been newly initiated on treatment.
Tammie Lee Demler, BS, PharmD, BCPP, MBA; Stephanie Keller-Wilcott, PharmD, BCPP; and Terrance J. Bellnier, RPh, MPA, FASCP
The concomitant use of intramusclar lorazepam with olanzapine or ziprasidone appears to be safe and well tolerated in severely mentally ill patients with acute agitation.
Supplements
Advertisement
Advertisement
